TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family

Breast Cancer Research and Treatment

Volumn 151, Issue 3, 2015, Pages 671-678

  Kappel, Sonja ^a   Janschek, Elisabeth ^b   Wolf, Brigitte ^a   Rudas, Margaretha ^a   Teleky, Bela ^a   Jakesz, Raimund ^a   Kandioler, Daniela ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Pediatrics and Adolescent Medicine   (Austria)

Author keywords

Cytotoxic treatment; Li Fraumeni syndrome; p53; Radiation

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; AUSTRIAN; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; ESOPHAGUS CANCER; EXON; FAMILIAL CANCER; FEMALE; FIBROSARCOMA; GENETIC ASSOCIATION; GERMLINE MUTATION; HEMANGIOPERICYTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MIDDLE AGED; MISSENSE MUTATION; OSTEOSARCOMA; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; RECTUM CANCER; SANGER SEQUENCING; SECOND CANCER; SEQUENCE ANALYSIS; SKIN CANCER; SKIN METASTASIS; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; YOUNG ADULT; AUSTRIA; BREAST NEOPLASMS; COMPLICATION; DNA MUTATIONAL ANALYSIS; FAMILY; GENETIC PREDISPOSITION; GENETICS; LI-FRAUMENI SYNDROME; ONSET AGE; PEDIGREE; TREATMENT OUTCOME;

PROTEIN P53;

ADOLESCENT; ADULT; AGE OF ONSET; AUSTRIA; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; MIDDLE AGED; PEDIGREE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84930272290     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3424-1     Document Type: Article

References (39)

1. Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71(4):747–752
2. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358–5362
3. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150(1):1–13
4. Varley JM (2003) Germline TP53 mutations and Li–Fraumeni syndrome. Hum Mutat 21(3):313–320
5. Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van ‘t Veer LJ (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47(6):421–428. doi:10.1136/jmg.2009.073429
6. NCCN (2014) National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian. Version 1. Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
7. McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, Thomas DM, Mitchell G (2014) Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 11(5):260–271. doi:10.1038/nrclinonc.2014.41
8. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP (1998) Multiple primary cancers in families with Li–Fraumeni syndrome. J Natl Cancer Inst 90(8):606–611
9. Nutting C, Camplejohn RS, Gilchrist R, Tait D, Blake P, Knee G, Yao WQ, Ross G, Fisher C, Eeles R (2000) A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 12(5):300–304
10. Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, Pachet C, Mathieu MC, Marsiglia H, Bourgier C (2010) Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li–Fraumeni syndrome. Radiat Oncol 5:104. doi:10.1186/1748-717X-5-104
11. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP (2001) Two metachronous tumors in the radiotherapy fields of a patient with Li–Fraumeni syndrome. Int J Cancer 96(4):238–242
12. Kamihara J, Rana HQ, Garber JE (2014) Germline TP53 mutations and the changing landscape of Li–Fraumeni syndrome. Hum Mutat 35(6):654–662. doi:10.1002/humu.22559
13. Wallace-Brodeur RR, Lowe SW (1999) Clinical implications of p53 mutations. Cell Mol Life Sci 55(1):64–75
14. Hematulin A, Sagan D, Sawanyawisuth K, Seubwai W, Wongkham S (2014) Association between cellular radiosensitivity and G1/G2 checkpoint proficiencies in human cholangiocarcinoma cell lines. Int J Oncol 45(3):1159–1166. doi:10.3892/ijo.2014.2520
15. Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kuhrer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Potter R, Jakesz R, Teleky B, Herbst F (2002) TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 235(4):493–498
16. McIlwrath AJ, Vasey PA, Ross GM, Brown R (1994) Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 54(14):3718–3722
17. Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zochbauer-Muller S, Kuhrer I, Mittlbock M, Zwrtek R, Aigner C, Bichler C, Tichy V, Hudec M, Bachleitner T, End A, Muller MR, Roth E, Klepetko W (2008) Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J Thorac Cardiovasc Surg 135(5):1036–1041. doi:10.1016/j.jtcvs.2007.10.072
18. Kandioler D, Schoppmann SF, Zwrtek R, Kappel S, Wolf B, Mittlbock M, Kuhrer I, Hejna M, Pluschnig U, Ba-Ssalamah A, Wrba F, Zacherl J, Zacherl J (2014) The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 research group study. J Thorac Cardiovasc Surg. doi:10.1016/j.jtcvs.2014.1006.1079
19. Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, Glimelius B, Cervantes A, Dewdney A, Wotherspoon A, Brown G, Tait D, Oates J, Chau I (2014) TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J Natl Cancer Inst. doi:10.1093/jnci/dju121
20. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100(14):8424–8429. doi:10.1073/pnas.1431692100
21. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622–629. doi:10.1002/humu.20495
22. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233–1238
23. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, Da Rocha JC, Vettore AL, Hainaut P (2007) The TP53 mutation, R337H, is associated with Li–Fraumeni and Li–Fraumeni-like syndromes in Brazilian families. Cancer Lett 245(1–2):96–102
24. Fiszer-Maliszewska L, Kazanowska B, Padzik J (2009) p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li–Fraumeni syndrome and a child with adrenocortical carcinoma. Fam Cancer 8(4):541–546
25. Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugieres L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T, The French LFS working group (2008) Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families. J Med Genet 45(8):535–538. doi:10.1136/jmg.2008.057570
26. Chene P (2001) The role of tetramerization in p53 function. Oncogene 20(21):2611–2617
27. Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:101–124
28. Etzold A, Schroder JC, Bartsch O, Zechner U, Galetzka D (2014) Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li–Fraumeni syndrome. Fam cancer. doi:10.1007/s10689-014-9754-z
29. Rollenhagen C, Chene P (1998) Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain. Int J Cancer 78(3):372–376
30. Camplejohn RS, Rutherford J (2001) p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours. Cell Prolif 34(1):1–14
31. Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I, Straub A, Schmitt B, Bettendorf H, Iggo R, Bauknecht T (2001) Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 60(2):176–188
32. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale AL (2006) The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin Cancer Res 12(4):1157–1167. doi:10.1158/1078-0432.CCR-05-1029
33. Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, De Rocquancourt A, Giacchetti S, Marty M, Calvo F (1994) p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 69(6):1145–1150
34. Izawa N, Matsumoto S, Manabe J, Tanizawa T, Hoshi M, Shigemitsu T, Machinami R, Kanda H, Takeuchi K, Miki Y, Arai M, Shirahama S, Kawaguchi N (2008) A Japanese patient with Li–Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the p53 tumor-suppressor gene. Int J Clin Oncol 13(1):78–82
35. Salmon A, Amikam D, Sodha N, Davidson S, Basel-Vanagaite L, Eeles RA, Abeliovich D, Peretz T (2007) Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clin Oncol (R Coll Radiol) 19(7):490–493
36. Warren S, Sommer GN (1936) Fibrosarcoma of the soft parts with special reference to recurrence and metastasis. Arch Surg 33:425–450
37. Sheppard DG, Libshitz HI (2001) Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases. Clin Radiol 56(1):22–29. doi:10.1053/crad.2000.0599
38. Zhang SS, Huang QY, Yang H, Xie X, Luo KJ, Wen J, Cai XL, Yang F, Hu Y, Fu JH (2013) Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis. Ann Surg Oncol 20(7):2419–2427. doi:10.1245/s10434-012-2859-4
39. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G, Jakesz R (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6(1):50–56